Scientific deep-dive

GLP-1 Drugs After 65: Strength, Not Just Weight

Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite, and a 2024 review found no concise guidelines for this age group.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·3 citations

The reassuring finding about muscle comes from trials in general adult populations, and it is real. Handgrip strength has held up in short and medium-term trials of semaglutide and liraglutide even while lean soft tissue fell.[1] The trouble is that the picture changes in the group most likely to be harmed by muscle loss. Longitudinal and retrospective research in older adults with type 2 diabetes reports the opposite: reduced grip strength and accelerated sarcopenia with prolonged semaglutide use.[1] A 2024 review found no concise guidelines for prescribing these drugs after 65.[3] The studies that do include older adults, none of them designed around them, are gathered in our after-65 reading list.

Mass and strength are not the same measurement

Most of the argument about muscle on these drugs is about mass, because mass is what a DXA scanner measures and what body-composition substudies report. Our lean mass article works through that evidence, and the short version is more reassuring than the headlines: lean tissue accounts for roughly a quarter to a third of weight lost, and intensive lifestyle programs cost a comparable share.

Strength is a different variable. It is what decides whether someone can rise from a chair without using their arms, carry shopping, or recover a stumble instead of falling. Grip strength is the standard proxy, and it is one of the defining components of sarcopenia in its own right.

Strength decides whether someone can rise from a chair without using their arms.

What the strength evidence shows, by age

Summarized from a 2026 review of GLP-1 drugs and muscle strength. All of it is short-to-mid-term or observational; no trial has been designed around this question in older adults.
PopulationWhat was observed
Adults with obesity, short to mid-term trialsGrip strength statistically preserved despite reductions in lean soft-tissue mass — strength did not fall in proportion to weight[1]
Older adults with type 2 diabetes, prolonged useReduced grip strength and accelerated sarcopenia in longitudinal and retrospective research[1]

Two things separate the last row from the first. One is age, and the fact that muscle mass and strength are already declining before any drug is involved. The other is duration: the reassuring results come from short and medium-term trials, and the concerning ones from prolonged use. A treatment intended to continue indefinitely is not well described by a 68-week trial.

These are observational findings, and that cuts both ways. Retrospective data in older adults with diabetes cannot separate the drug from the aging, the diabetes, or the illness that prompted the prescription. It is a signal worth taking seriously, not a settled result, and it argues for running the trial instead of for either reassurance or alarm.

Who carries the most risk

A 2025 review looked at the groups already predisposed to sarcopenia before a GLP-1 enters the picture, and made the obvious but under-stated point: the same proportional loss lands harder on someone with less reserve.[2] It puts lean mass at as much as 15 to 40% of total weight lost, and notes that evidence on body composition is insufficient in older adults, and equally so in chronic kidney disease, liver disease and inflammatory bowel disease.

  • Anyone already frail, or recently hospitalized. Reserve is the variable, not percentage lost.
  • Anyone with sarcopenic obesity (high fat and low muscle together). It is common after 65 and easy to miss because the scale looks like a straightforward obesity problem.[3]
  • Anyone eating substantially less than they were. The appetite suppression that drives the weight loss can also undercut protein intake, at the age when protein matters most.
  • Anyone not doing resistance work. The reviews agree on this even where they agree on little else.

A 2024 review of obesity pharmacotherapy in adults 65 and over found the general-population efficacy and safety data increasingly favorable, but concise guidelines for older adults unavailable.[3] It calls for trials that measure geriatric outcomes rather than weight alone.

So a prescriber weighing this for someone in their seventies is extrapolating from trials whose average participant was decades younger, without a guideline to work from. An effective drug can still be the right call for an older patient, but the usual scaffolding is missing, so it is worth asking what is being monitored instead.

The reviews do converge on two unglamorous things: adequate protein, and resistance training, from the start rather than after a loss.[2] Our protein calculator works a target from body weight, and the exercise pairing tool sets out the training side. For the same question framed around the menopausal transition rather than age 65, see GLP-1 drugs after menopause.

Frequently Asked Questions

The general-population efficacy and safety data are increasingly favorable, but a 2024 review found no concise guidelines written for this age group, and trials measuring geriatric outcomes rather than weight are what reviewers keep asking for. A prescriber is extrapolating from trials whose participants were decades younger.
The evidence splits by age. Short-to-mid-term trials in adults with obesity found grip strength statistically preserved despite lean mass falling. Longitudinal and retrospective research in older adults with type 2 diabetes reported reduced grip strength and accelerated sarcopenia with prolonged use. The second set is observational and cannot separate the drug from aging or diabetes.
Not necessarily, and that is the useful part. Mass is what a DXA scanner measures; strength is what determines whether someone can rise from a chair or recover a stumble. In several trials strength held up better than mass did, which is why grip strength is worth asking about rather than body composition alone.
The reviews converge on adequate protein intake and resistance training, started alongside the drug rather than after a loss has happened. That is consistent advice across sources that disagree about much else.
Nothing here says that, and obesity in later life carries its own serious costs. The argument is about measuring strength and function, not only the number on the scale, and about knowing that the guideline scaffolding a prescriber would normally rely on was still missing for this age group as of 2024.

References

  1. 1.Prokopidis K. Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions British Journal of Pharmacology. 2026. PMID: 41577337.
  2. 2.Memel Z, Gold SL, Pearlman M, et al. Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia Current Nutrition Reports. 2025. PMID: 40289060.
  3. 3.Žižka O, Haluzík M, Jude EB. Pharmacological Treatment of Obesity in Older Adults Drugs & Aging. 2024. PMID: 39514148.

Ozempic and the Vagina: Dryness, Odor and Yeast Infections

No GLP-1 label lists a vaginal side effect. Genital yeast infections belong to SGLT2 diabetes drugs such as Jardiance, and GLP-1 users had fewer of them in cohort studies. What FDA reports show, likely causes of dryness and odor, and when to see a clinician.

11 min read

Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.

10 min read

Eating Too Little on a GLP-1: What the Deficiency Data Show

Across 480,825 adults, more than 60% took in less calcium and iron than their estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.

7 min read

Holding a GLP-1 Before Endoscopy or Surgery: What the Trial Found

A 2026 randomized trial put retained stomach contents at 3.1% when one dose was held against 25.0% when it was not, and found something more useful about the day-before diet.

7 min read

GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026

In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.

7 min read

Phentermine and a GLP-1 Together: What the Labels and Trials Show

Phentermine's label says combining it with any other weight-loss drug is not recommended; the Wegovy and Zepbound labels never mention it. The one trial, with liraglutide, found no meaningful extra loss. No semaglutide or tirzepatide trial exists.

10 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Luvo Health

Moving between compounded and brand without changing seller

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →